3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Medullary
9
Lung Neoplasms
8
Thyroid Neoplasms
7
Neoplasms
5
Neoplasm Metastasis
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
13
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Docetaxel
6
Axitinib
6
Albumin-Bound Paclitaxel
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Nivolumab
5
Erlotinib Hydrochloride
5
Cyclophosphamide
5
Sorafenib
4
Radiation
4
Irinotecan
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
vandetanib
×
Clear all
No trials found.